• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.
【24h】

Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.

机译：在奥氮平治疗的精神分裂症或精神分裂症患者中，体重管理程序可用于治疗后体重的突然增加：一项为期12周的随机对照临床试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The main objective was to assess the efficacy of a weight management program designed for outpatients taking olanzapine for schizophrenia or schizoaffective disorder and to compare these patients with a randomized control group. The effects of the weight management program were also assessed with regard to safety and quality of life. METHOD: Forty-eight patients were enrolled in a 12-week, randomized, multicenter weight management study. Thirty-three patients were randomly allocated to an intervention group in which they received olanzapine within a weight management program. Fifteen patients were allocated to a control group in which they were given olanzapine treatment as usual outpatients. Weight, body mass index (BMI), and measurements of safety and quality of life were evaluated. The study was conducted from January 7, 2003, to September 16, 2003. RESULTS: Thirty-six patients (75%) completed this study. We found significant differences in weight (-3.94 +/- 3.63 kg vs. -1.48 +/- 1.88 kg, p = .006) and BMI (-1.50 +/- 1.34 vs. -0.59 +/- 0.73, p = .007) change from baseline to endpoint between the intervention and control groups, respectively. Significant differences in weight reduction were initially observed at week 8 (p = .040). No significant differences were found with regard to the safety outcomes. When the ratio of low-density lipoproteins to high-density lipoproteins was calculated, change from baseline was greater in the intervention group than the control group (-0.19 vs. -0.04), but the difference was not statistically significant (p = .556). After the completion of the weight management program, there was a trend toward statistical difference in the physical health score changes between the weight management and control groups (1.12 in the intervention group vs. -0.93 in the control group, p = .067). CONCLUSION: The weight management program was effective in terms of weight reduction in patients with schizophrenia or schizoaffective disorder taking olanzapine and was also found to be safe in terms of psychiatric symptoms, vital signs, and laboratory data. In addition, such a weight management program might improve quality of life in patients with schizophrenia or schizoaffective disorder with respect to their physical well-being.
机译：背景：主要目的是评估针对服用奥氮平治疗精神分裂症或精神分裂症的门诊患者设计的体重管理计划的疗效，并将这些患者与随机对照组进行比较。体重管理计划的效果也就安全性和生活质量进行了评估。方法：48位患者参加了为期12周的随机多中心体重管理研究。 33例患者被随机分配到干预组，在体重控制程序中接受奥氮平治疗。十五名患者被分配到对照组，他们像往常一样接受奥氮平治疗。评估了体重，体重指数（BMI）以及安全性和生活质量的度量。该研究于2003年1月7日至2003年9月16日进行。结果：36位患者（75％）完成了这项研究。我们发现体重（-3.94 +/- 3.63公斤与-1.48 +/- 1.88公斤，p = .006）和BMI（-1.50 +/- 1.34相对-0.59 +/- 0.73，p =。 007）干预组和对照组之间从基线到终点的变化。最初在第8周观察到减肥的显着差异（p = .040）。在安全结果方面未发现显着差异。当计算低密度脂蛋白与高密度脂蛋白的比率时，干预组的基线变化较对照组大（-0.19 vs.-0.04），但差异无统计学意义（p = .556） ）。体重管理计划完成后，体重管理与对照组之间的身体健康评分变化呈现出统计差异的趋势（干预组为1.12，对照组为-0.93，p = .067）。结论：体重减轻计划在服用奥氮平的精神分裂症或精神分裂症患者的减肥方面有效，并且在精神病症状，生命体征和实验室数据方面也很安全。另外，这样的体重管理程序可以改善精神分裂症或精神分裂症患者的身体健康状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号